Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131911 · ClinicalTrials.gov registry record · Phase 2
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
A Phase 2 study of Neuroendocrine Tumor and Insulinoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
- 1
- Study location
NCT00131911: Completed Phase 2 study of Neuroendocrine Tumor and Insulinoma, sponsored by National Cancer Institute (NCI).
NCT00131911 is a Phase 2 study of Neuroendocrine Tumor and Insulinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 93 participants, below the 129-participant average among 6 other Neuroendocrine Tumor trials with a reported enrollment target (28% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00131911, a Phase 2 study of Neuroendocrine Tumor and Insulinoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well sorafenib tosylate works in treating patients with progressive metastatic neuroendocrine tumors. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Primary Outcome
Confirmed response rate was defined using Response Evaluation Criteria In Solid Tumors (RECIST). A confirmed response is defined as a complete response (CR) or partial response (PR) observed on subsequent scans at least 4 weeks apart. Confirmed response rate was estimated by the number of successes divided by the total number of evaluable patients.\> \> Complete Response (CR) is defined as the disappearance of all target lesions.\> Partial Response (PR) is defined as a 30% decrease in sum of lon
Conditions Studied
Interventions
- DRUG sorafenib tosylate
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2005-06 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
What the finished NCT00131911 record still lists
NCT00131911 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 129-participant average among 6 other Neuroendocrine Tumor trials with a reported enrollment target (28% lower).
The record links to 10 conditions, with Neuroendocrine Tumor appearing as the primary indexed condition, and to 1 intervention - of which sorafenib tosylate is the first listed.
NCT00131911 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00131911 about?
NCT00131911 is a clinical study titled "Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors". This phase II trial is studying how well sorafenib tosylate works in treating patients with progressive metastatic neuroendocrine tumors. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
What is the current status of trial NCT00131911?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2005-06. Estimated completion is 2013-04.
What conditions does trial NCT00131911 study?
This clinical trial studies the following conditions: Neuroendocrine Tumor, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Gastrinoma, Glucagonoma.
What interventions are being tested in trial NCT00131911?
The interventions under investigation include: sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT00131911?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00131911 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
COMPLETED · Phase 2
-
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
COMPLETED · Phase 2
-
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
RECRUITING · Early Phase 1
-
Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
RECRUITING · NA
-
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia